Cargando…

Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19”

Detalles Bibliográficos
Autores principales:	Nicolini, Laura Ambra, Mikulska, Malgorzata, Signori, Alessio, Di Biagio, Antonio, Portunato, Federica, Vena, Antonio, Giacomini, Mauro, Bassetti, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443101/ https://www.ncbi.nlm.nih.gov/pubmed/32855991 http://dx.doi.org/10.1093/ofid/ofaa321

Ejemplares similares

Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19
por: Chen, Jun, et al.
Publicado: (2020)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations
por: Taramasso, Lucia, et al.
Publicado: (2020)

Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations
por: Gutierrez‐Valencia, Alicia, et al.
Publicado: (2018)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

Data on the stability of darunavir/cobicistat suspension after tablet manipulation
por: Zanon, D., et al.
Publicado: (2020)

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients
por: López-Ruz, Miguel A., et al.
Publicado: (2018)

Validation of an Automated System for the Extraction of a Wide Dataset for Clinical Studies Aimed at Improving the Early Diagnosis of Candidemia
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2023)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
por: Putcharoen, Opass, et al.
Publicado: (2015)

Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination
por: Dentone, Chiara, et al.
Publicado: (2022)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
por: Squillace, Nicola, et al.
Publicado: (2018)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro, Jordi, et al.
Publicado: (2016)

Ceftriaxone/cobicistat/darunavir/hydroxychloroquine: Off-label use and lack of efficacy: case report
Publicado: (2022)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
por: Di Castelnuovo, Augusto, et al.
Publicado: (2021)

Ten Years of Medical Informatics and Standards Support for Clinical Research in an Infectious Diseases Network
por: Mora, Sara, et al.
Publicado: (2023)

Early Detection of Sepsis With Machine Learning Techniques: A Brief Clinical Perspective
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2021)

Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
por: Kim, Eun Jin, et al.
Publicado: (2020)

Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
por: Elmekaty, Eman Zeyad I., et al.
Publicado: (2022)

Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression
por: Vena, Antonio, et al.
Publicado: (2022)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
por: Prinapori, Roberta, et al.
Publicado: (2015)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
por: Chow, Wing, et al.
Publicado: (2020)

Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations
por: Stillemans, Gabriel, et al.
Publicado: (2020)

Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2
por: Dettori, Silvia, et al.
Publicado: (2022)

Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care
por: Taramasso, Lucia, et al.
Publicado: (2021)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir
por: Chen, Ying, et al.
Publicado: (2022)

Challenges in the diagnosis and treatment of candidemia due to multidrug-resistant Candida auris
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2023)

Combining immunomodulators and antivirals for COVID-19 – Authors' reply
por: Almansa, Raquel, et al.
Publicado: (2021)

Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy
por: Vena, Antonio, et al.
Publicado: (2020)

Sensitivity of Serum Beta-D-Glucan in Candidemia According to Candida Species Epidemiology in Critically Ill Patients Admitted to the Intensive Care Unit
por: Mikulska, Malgorzata, et al.
Publicado: (2022)

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
por: Eron, Joseph J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5140cu1s5o8tpnjd2e9v54ujli